Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple material claims conflict with the provided FDA label excerpts (indications for UTIs and respiratory tract infections; efficacy/susceptible-strain statements). Several mechanism and efficacy statements are unsupported by the provided MICROBIOLOGY excerpt, and multiple additional claims (trade name/patent/generics) are not verifiable from the supplied label sections.
Category Scores
Accurate Statements
Ampicillin sulbactam combines ampicillin, a beta-lactam antibiotic, with sulbactam, a beta-lactamase inhibitor.
DESCRIPTION: “injectable antibacterial combination consisting of … ampicillin … and the beta-lactamase inhibitor sulbactam”
Sulbactam inhibits beta-lactamase enzymes produced by bacteria, making bacteria more susceptible to ampicillin.
MICROBIOLOGY: “beta-lactamases … have been shown … to be irreversibly inhibited by sulbactam” and “sulbactam restores ampicillin activity against beta-lactamase producing strains”
Unsupported Statements
Ampicillin sulbactam has a synergistic effect on ampicillin-sensitive bacteria, enhancing the bactericidal activity of ampicillin.
Not supported; MICROBIOLOGY states: “Sulbactam has no effect on the activity of ampicillin against ampicillin susceptible strains.”
By inhibiting beta-lactamases, sulbactam allows ampicillin to penetrate the bacterial cell wall, resulting in more effective killing.
Partially supported only for beta-lactamase inhibition and restoration of ampicillin activity; the provided excerpts do not support “penetrate the bacterial cell wall” or “more effective killing.”
Ampicillin sulbactam disrupts bacterial cell membranes, ultimately leading to cell lysis.
The provided MICROBIOLOGY excerpt describes inhibition of “cell wall mucopeptide biosynthesis” but does not mention membrane disruption or cell lysis.
The sulbactam component enables ampicillin to bind to penicillin-binding proteins (PBPs) on the bacterial cell wall.
No PBP binding mechanism is present in the provided label excerpts.
Ampicillin binding to PBPs inhibits cross-linking of peptidoglycan, a critical component of the cell wall.
No PBPs/peptidoglycan cross-linking mechanism is present; excerpt instead states inhibition of “cell wall mucopeptide biosynthesis.”
Inhibition of peptidoglycan cross-linking weakens the bacterial cell membrane and leads to cell death.
No support in provided excerpts linking these mechanistic steps to membrane weakening/cell death.
Ampicillin sulbactam exhibited superior efficacy against a range of Gram-positive bacteria compared to ampicillin alone.
The provided MICROBIOLOGY excerpt does not explicitly state “superior efficacy” vs ampicillin alone for Gram-positive bacteria.
Ampicillin sulbactam is available under the trade name Unasyn.
Trade name information is not present in the provided label excerpts.
The patent for ampicillin sulbactam expired in 2001.
Patent/timeline information is not present in the provided label excerpts.
Generic versions of ampicillin sulbactam entered the market after the patent expiration.
Generic market-entry information is not present in the provided label excerpts.
Several generic versions of ampicillin sulbactam are currently available.
Current generics availability information is not present in the provided label excerpts.
Contradictions
Low
AI Statement
Studies have shown that ampicillin sulbactam is more effective against ampicillin-sensitive bacteria than ampicillin alone.
Label Reference
MICROBIOLOGY: “Sulbactam has no effect on the activity of ampicillin against ampicillin susceptible strains.”
Low
AI Statement
Ampicillin sulbactam is approved by the US FDA for urinary tract infections.
Label Reference
INDICATIONS AND USAGE (provided): Skin and Skin Structure Infections; Intra-Abdominal Infections; Gynecological Infections. Urinary tract infections not included.
Low
AI Statement
Ampicillin sulbactam is approved by the US FDA for respiratory tract infections.
Label Reference
INDICATIONS AND USAGE (provided): Skin and Skin Structure Infections; Intra-Abdominal Infections; Gynecological Infections. Respiratory tract infections not included.
Important Omissions
If claiming clinical use, the label excerpts specify that infections should be due to susceptible strains and that appropriate culture/susceptibility testing should be performed before treatment (with possible initial therapy prior to results). These operational statements were not included in the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Contradicted FDA-label indication claims (UTIs and respiratory tract infections) could misdirect intended use. Multiple unsupported/incorrect mechanism and efficacy statements may also mislead interpretation of activity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Indication claims directly contradict the provided INDICATIONS AND USAGE excerpt, and multiple efficacy/mechanism claims conflict with or are unsupported by the provided MICROBIOLOGY excerpt.
Suggested Improvement
Limit claims to what is explicitly supported in the provided excerpts (DESCRIPTION; MICROBIOLOGY beta-lactamase inhibition and restoration for beta-lactamase producing strains; the specific labeled indication organ systems). Remove unsupported mechanistic steps (PBPs/cross-linking/membrane disruption/lysis) and any efficacy statements that contradict “no effect” on ampicillin-susceptible strains. Do not assert labeled indications not present in the provided INDICATIONS AND USAGE section.